Cisplatin lung toxicity

Author: dzxp

August undefined, 2024

WebAlthough the final mechanism of inducing tumour cell apoptosis is similar for both compounds, cisplatin has been shown to be more effective in treating specific tumour types. Whilst more favourable toxicity profiles are often associated with carboplatin, this can frequently translate to inferior response in certain malignancies. WebMar 22, 2024 · Pulmonary toxicities occur in 10% of treated patients. In approximately 1%, the nonspecific pneumonitis induced by Bleomycin progresses to pulmonary fibrosis and death. Although this is age and …

Cisplatin - an overview ScienceDirect Topics

WebFeb 22, 2024 · Lung cancer is the leading cause of cancer-related death in the Unites States, and approximately 85% of all lung cancers are classified as non-small cell lung … WebMay 9, 2024 · This topic review will provide an overview of the incidence and specific patterns of lung toxicity seen with cytotoxic chemotherapy agents. Separate … solar panels money back

Clinical comparative investigation of efficacy and toxicity of ...

WebDec 7, 2024 · In the present study, the carboplatin-containing regimen was associated with a higher incidence of thyroid and pulmonary toxicity. Therefore, for patients with co … WebChemotherapy-related cardiac toxicity is a rare but serious adverse event in patients with cancer. Thus far, no case of serious cardiac toxicity of pemetrexed has been reported. We describe the case of a patient with advanced lung cancer and cardiomyopathy due to … solar panels mohave county

Cisplatin: a review of toxicities and therapeutic applications

Cisplatin in cancer therapy: molecular mechanisms of action

WebThus, the SNP rs10505477 in CASC8 may serve as an underlying risk marker for detecting and diagnosing lung cancer, and could be used to determine the response and toxicity of platinum-based chemotherapy in lung cancer patients. However, further larger well-designed studies will be needed to clarify the biological and clinical significance of ... WebAbstract Cisplatin (DDP) is a common therapeutic option for non-small cell lung carcinoma (NSCLC). However, some patients fail to respond to the DDP chemotherapy. ... Targeted … solar panels mounted on groundWebNov 12, 2024 · Commonly reported side effects of cisplatin include: bone marrow depression, nephrotoxicity, and ototoxicity. Continue reading for a comprehensive list of … solar panels montgomery ind

"WebSep 4, 2013 · Short hydration is safe and reduces the frequency of severe renal toxicities in regimens containing cisplatin (≥75 mg/m 2) for the treatment of patients with lung cancer. Cisplatin labels with regard to hydration should accept short- and lower-volume hydration as an option based on the result of the present study. Funding " - Cisplatin lung toxicity

Cisplatin lung toxicity

WebJun 1, 2016 · The carboplatin-docetaxel arm had a more favourable toxicity profile and a significant number of patients withdrew from the cisplatin-docetaxel doublet due to grade 3–4 emesis ( Greco et al., 2000 ). Other studies have observed the efficacy and tolerability of platinum-gemcitabine regimens in CUP. WebClinical Comparative Investigation of Efficacy and Toxicity of Cisplatin plus Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer Dan Ai,1,2 Yan Guan,2 Xiu-Ju Liu,2 Chu-Feng Zhang,1,2 Peng Wang,1,2 Hong-Lu Liang,1,2 Qi …

Did you know?

WebToxicological effects of cisplatin are diverse and have been an area of concern for many oncologists, practitioners and researchers. Nausea and Vomiting are considered as the … Web1. INTRODUCTION. Lung cancer has a high worldwide prevalence and is usually malignant, with the highest cancer‐related mortality. 1 , 2 Lung cancers can be grossly classified into non‐small cell lung carcinoma (NSCLC), accounting for about 85% of lung cancers, and small cell lung carcinoma, which is less prevalent. NSCLC can be further …

WebDec 7, 2024 · The EC regimen was associated with a higher risk of grade 1–2 haematological toxicities, including anaemia, thrombocytopaenia, hypothyroidism, dyspnoea, infection, hypertension and arrythmia (all p < 0.001), hyponatremia ( p = 0.022) and pneumonia ( p = 0.013), whereas patients who underwent the EP regimen were more … WebNov 29, 2024 · Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment Yanyun Gao, Patrick Dorn, Shengchen Liu, Haibin Deng, Sean R. R. Hall, Ren-Wang Peng, Ralph A. Schmid & Thomas M. Marti Cancer Cell International 19, Article number: 317 ( 2024 ) …

Webovarian, testicular, head, neck and small cell lung cancer for the last four decades1. Acquired resistance following initial use in ovarian and small cell lung carcinoma has been documented, whereas tumors like colorectal ... toxicity of Cisplatin in a median follow up time of 58 months identified cardiovascular risk factors in one third WebPulmonary toxicity of cytotoxic agents Platinum compounds The administration of cisplatin and carboplatin, the 2 most commonly used platinum derivative agents, can lead to …

WebJun 1, 2013 · It has been shown that cisplatin administration induced a large amount of NO, which may lead to a greater formation of ROS and RNS causing cellular damage …

WebSep 15, 2024 · Cisplatin is mutagenic, teratogenic and carcinogenic and its use has been show to increase the risk of secondary malignancies, particularly leukemia. … solar panels manufacturer indiaWebCisplatin, a platinum analogue, is an alkylating agent used in combination with other agents to treat a variety of solid malignancies, including lung cancer, head and neck cancer, mesothelioma, ovarian cancer, and bladder cancer. It is also used prior to bone marrow and stem cell transplantation. solar panels morgan countyWebThe TPF triplet regimen (docetaxel, cisplatin, and 5‐FU) has a trend of further improving treatment efficacy compared with the traditional doublet regimen. 35 , 36 In a phase II study, concurrent chemoradiotherapy with TPF achieved a clinical CR rate of 52.4%, much higher than the previously reported CR rate of 20%. 9 However, the high ... slushy howlerWebThis suggests that cisplatin-induced lung damage can damage the cilia, manifesting as increased ciliary proteins in the BALF. By increasing oxidative stress in the lung, … solar panels mounted on postsWebJan 23, 2024 · The major toxicities occur in the lung and skin, where the drug is concentrated. Up to 20% of patients treated with bleomycin develop clinical pulmonary … solar panels mount pleasantWebAdverse effects of RT-CT were grades 3 to 4 neutropenia (four patients) and grade 3 esophageal toxicity (one patient). No treatment-related deaths occurred. Conclusion: The oral vinorelbine-cisplatin combination with concurrent RT is feasible and has a favorable risk-benefit ratio in stage IIIA/IIIB NSCLC. Publication types solar panels mounted portable trailerWebSep 15, 2024 · Cisplatin is mutagenic, teratogenic and carcinogenic and its use has been show to increase the risk of secondary malignancies, particularly leukemia. Hepatotoxicity The platinum compounds generally are not considered to be hepatotoxic, but cisplatin has been associated with a low rate of serum enzyme elevations during therapy. solar panels monocrystalline polycrystalline